DelveInsight’s “Rosacea Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Rosacea, historical and forecasted epidemiology as well as the Rosacea market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Rosacea market report provides current treatment practices, emerging drugs, Rosacea market share of the individual therapies, current and forecasted Rosacea market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Rosacea treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Rosacea market.
Rosacea: An Overview
Rosacea is a characteristic condition that affects the skin by causing facial erythema or redness. Around one in 10 people in the world is affected by rosacea. The symptoms of the disease manifest in various combinations and severity that often fluctuates between periods of exacerbation and remission. It is a common skin condition that causes redness and visible blood vessels in central part of the face. It may also produce small, red, pus-filled bumps.
Download a sample copy of the rosacea market report @ https://www.delveinsight.com/sample-request/rosacea-market
Some of the key highlights of the Rosacea Market Report
- As per a study by Tan et al. (2016), titled “Prevalence of rosacea in the general population of Germany and Russia – The RISE study,” a total of 3,052 and 3,013 subjects (aged 18–65 years) were screened in Germany and Russia respectively. Rosacea prevalence was 12.3% in Germany. Overall, 18% of subjects diagnosed with rosacea were aged 18–30 years. Demographics of rosacea subjects with a confirmed diagnosis were similar in Germany and Russia. In Germany, 74.4% (61/82) were females. In Germany, erythematotelangiectat, papulopustular, phymatous and ocular subtypes were found in 69.5% (57/82), 30.5% (25/82), 4.9% (4/82), and 7.3% (6/82) of patients.
- According to Tan et al. (2016), in Germany, 74.4% were females as compared to males.
- As per the article by Mandal (n.d.), titled “Rosacea Epidemiology,” in the United States, the prevalence of rosacea seems to be on the rise and in the United Kingdom, the prevalence is 1.65 per 1000 person-years. There is a paucity of epidemiological data on rosacea, with reported prevalence rates ranging from as little as 0.09% to as much as 22.00%.
Rosacea Epidemiology Insights
Rosacea is a condition in which rashes develop on the skin, involving the central face and it most often starts between the age of 30 and 60 years. It is common in those with fair skin, blue eyes and Celtic origins. It may be transient, recurrent or persistent and is characterized by its color, red. The disorder is more frequently diagnosed in women, but tends to be more severe in men. There is also evidence that rosacea may tend to run in families, and may be especially prevalent in people of northern or eastern European descent.
Rosacea Epidemiology Segmentation in the 7MM
- Total Prevalent Population
- Gender-Specific Prevalent Population
- Diagnosed Prevalence
- Subtype Specific Diagnosed Prevalence
- Severity-specific Prevalence
Rosacea Therapeutic Landscape
The current therapeutic landscape of Rosacea can be divided into four major categories based on the route of administration and the approved usage for the condition. These are: topical retinoids, topical antibiotics, oral tetracycline class antibiotics (TCAs), and oral retinoids.
Rosacea Market Insights
The approved (and their generic versions) as well as off-label products that are being used for the treatment of Rosacea, and contributing towards the market revenue, belong to either of these above-mentioned therapeutic categories. The effectiveness of approved therapies depend on the subtype as well as the severity of the disease. Due to these unmet need, many companies are developing the drugs for the treatment of rosacea.
Rosacea Treatment Market
Topical medications can be effective in improving pimples and pustules, and, for more challenging cases, anti-inflammatory medications such as doxycycline is helpful. However, the erythematous component of rosacea—the redness of the skin—is typically not improved by the current treatment modalities, and this remains an unmet need. Drugs that are in development have been designed to address this component of rosacea.
Rosacea Emerging Therapies
The emerging therapies for the treatment of Rosacea include Epsolay (formerly VERED), ACU-D1, AOB103, and others. There is an unmet need for effective therapies to address treatment-resistant and severe form of papulopustular rosacea. The interleukin (IL) 17 inhibitors might be useful in this case, require large scale studies. Another ongoing research is the use of laser or light therapy to manage rosacea.
Rosacea Market Dynamics
The dynamics of Rosacea market is anticipated to change in the coming years owing to the expected approval of emerging therapies during the forecasted period of 2021‒2030. There are presently several emerging therapies focused on the treatment of Rosacea that include Epsolay (Sol-Gel Technologies), ACU-D1 (Accuitis), and AOB103 (AOBiome).
Request a sample copy of the Rosacea Market Report- https://www.delveinsight.com/sample-request/rosacea-market
Table of Content
1. Key Insights
2. Executive Summary of Rosacea
3. Competitive Intelligence Analysis for Rosacea
4. Rosacea: Market Overview at a Glance
5. Rosacea: Disease Background and Overview
7. Rosacea Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Rosacea Unmet Needs
10. Key Endpoints of Rosacea Treatment
11. Rosacea Marketed Products
12. Rosacea Emerging Therapies
13. Rosacea: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Rosacea
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/